Research Overview
Peptides for Longevity
A structured overview of peptides researched in the context of aging, cellular repair, and healthspan extension.
Longevity peptide research addresses fundamental biological mechanisms of aging. However, the field is largely preclinical. No compound covered here is FDA-approved for anti-aging use.
What This Page Covers
This page covers peptides studied for their potential effects on aging-related biological pathways, including telomere maintenance, mitochondrial function, cellular senescence, and tissue regeneration. Evidence levels vary significantly; this is among the weakest evidence categories in the PSI condition library.
How Longevity Peptides Work
Mechanism 01
Epigenetic and Telomere Mechanisms
Peptides like Epitalon are studied for their potential to activate telomerase and influence epigenetic markers of aging, though human evidence is very limited.
Mechanism 02
Mitochondrial Protection
SS-31 stabilizes the inner mitochondrial membrane. MOTS-c and Humanin are mitochondrial-derived peptides that address metabolic and cytoprotective aspects of cellular aging.
Mechanism 03
Tissue Regeneration
GHK-Cu modulates gene expression involved in collagen synthesis and tissue remodeling. These pathways are relevant to skin aging and broader regenerative processes.
Peptides Commonly Discussed for Longevity
Ordered by evidence level.
Epitalon
Animal StudiesTelomerase activation / epigenetic
Synthetic tetrapeptide analog of epithalamin, researched for telomerase activation and potential epigenetic effects on aging.
GHK-Cu
Animal StudiesCopper-mediated tissue remodeling
Copper-binding tripeptide with research applications in skin regeneration, tissue remodeling, and gene expression modulation.
SS-31
Animal StudiesCardiolipin stabilization
Mitochondria-targeted peptide (Elamipretide) researched for mitochondrial dysfunction and age-related diseases. Has entered clinical trials.
MOTS-c
PreclinicalAMPK activation / metabolic signaling
Mitochondrial-derived peptide researched for metabolic regulation and exercise-mimetic effects. Very early stage.
Humanin
PreclinicalCytoprotective signaling
Mitochondrial-derived peptide with cytoprotective signals studied in neurodegenerative and metabolic disease models.
Pinealon
PreclinicalPineal gland / neuroprotection
Tripeptide of Russian origin researched for pineal gland function and neuroprotective effects. Very limited data.
Quick Comparison
| Peptide | Primary Mechanism | Evidence | Research Context |
|---|---|---|---|
| Epitalon | Telomerase activation / epigenetic | Animal Studies | Animal models and limited human pilot data |
| GHK-Cu | Copper-mediated tissue remodeling | Animal Studies | In vitro and topical human studies |
| SS-31 | Cardiolipin stabilization | Animal Studies | Phase 2/3 clinical trials for mitochondrial conditions |
| MOTS-c | AMPK activation / metabolic signaling | Preclinical | Primarily animal models; very early stage |
| Humanin | Cytoprotective signaling | Preclinical | Mostly animal and in vitro; single-group concentration |
| Pinealon | Pineal gland / neuroprotection | Preclinical | Mostly Russian literature; very limited |
What the Research Suggests
Best Evidence for Longevity
Longevity peptide research addresses fundamental biological mechanisms of aging. However, the field is largely preclinical. SS-31 is the only compound with significant clinical trial infrastructure, and its trials target mitochondrial diseases rather than longevity per se.
Strongest Individual Compound
GHK-Cu for topical skin regeneration (limited human data). SS-31 for mitochondrial dysfunction (clinical trials in progress). Epitalon for telomerase research (animal models with limited pilot human data).
What This Category Cannot Do
Half of the peptides in this category carry Preclinical evidence ratings. Longevity outcomes are inherently difficult to measure in clinical trials. Several compounds (Pinealon, Epitalon) have research concentrated in a single geographic region, limiting independent verification.
PSI Reading of the Evidence Gap
This is the weakest evidence category among PSI condition hubs. While the underlying biology is compelling, the distance between mechanistic hypotheses and validated human outcomes is substantial. Users should approach longevity peptide claims with heightened skepticism.
How to Choose
Research-informed guidance for peptides studied in the context of longevity. Not a recommendation.
Regulatory Status
6 available through compounding.
Important Limitations
Research-Only
- Epitalon
- MOTS-c
- Humanin
- Pinealon
All preclinical or very early-stage with no regulatory approval.
Topical Available
- GHK-Cu (available in cosmetic formulations)
Clinical Trials
- SS-31 (Elamipretide): Phase 2/3 for mitochondrial conditions, not anti-aging
No peptide in this category is FDA-approved for anti-aging or longevity indications.
Half of the peptides carry Preclinical evidence ratings.
Longevity outcomes are inherently difficult to measure in clinical trials.
Several compounds have research concentrated in a single geographic region.
The distance between mechanistic hypotheses and validated human outcomes is substantial.
Explore More
Related Hubs
Who This May Apply To
Individuals researching the evidence behind peptide-based anti-aging and longevity approaches.
Healthcare providers evaluating the spectrum from clinical-stage to preclinical longevity compounds.
Researchers studying telomere biology, mitochondrial function, and cellular senescence.
Related Conditions
This page is provided for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. The peptides discussed include both FDA-approved medications and research compounds that are not approved for clinical use. Always consult a qualified healthcare professional before making any decisions about medical treatments. The Peptide Science Institute is an independent research database and does not sell, prescribe, or recommend any compounds.